Demailly P, Arrata M
Ophthalmologica. 1980;181(3-4):221-7. doi: 10.1159/000309056.
A preselected population of 96 patients (67 glaucomas, 29 ocular hypertensions) were followed for an average period of 30 months. Timolol eye drops were administered either alone, in dosage strengths of 0.25 or 0.5% or in combination with other antiglaucoma drugs. 9 patients were lost to follow-up after a mean treatment duration of 15.3 months; glaucoma had been stabilized in all of them. 10 patients had unsatisfactory intraocular pressure control and 7 had to undergo trabeculectomy (9 of these 10 patients had campimetric glaucoma at the beginning of the study), whereas 76 patients had satisfactory intraocular pressure control and, in the majority, stabilization of glaucoma had been obtained. In 77% of this preselected population glaucoma was stabilized over a period of 3 years (i.e. close to two thirds of those starting treatment, 70% of which had campimetric glaucoma).
对预先选定的96名患者(67例青光眼患者,29例高眼压症患者)进行了平均30个月的随访。单独使用噻吗洛尔滴眼液,剂量分别为0.25%或0.5%,或与其他抗青光眼药物联合使用。9例患者在平均治疗15.3个月后失访;所有患者的青光眼病情均已稳定。10例患者眼压控制不理想,7例患者不得不接受小梁切除术(这10例患者中有9例在研究开始时患有视野计青光眼),而76例患者眼压控制良好,大多数患者的青光眼病情已得到稳定。在这个预先选定的人群中,77%的患者青光眼病情在3年内得到稳定(即接近三分之二开始治疗的患者,其中70%患有视野计青光眼)。